| Literature DB >> 29223990 |
Jeffrey Crawford, Pamela Sue Becker, James O Armitage, Douglas W Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A Griffiths, Shannon Hough, Dwight D Kloth, David J Kuter, Gary H Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S Rugo, Ayman A Saad, Lee S Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L Burns, Lenora Pluchino.
Abstract
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29223990 DOI： 10.6004/jnccn.2017.0175
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908